Front Row Advisors’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.6M | Buy |
5,290
+5
| +0.1% | +$2.71K | 0.88% | 32 |
|
|
2025
Q4 | $3.06M | Buy |
5,285
+8
| +0.2% | +$4.52K | 1.02% | 26 |
|
|
2025
Q3 | $2.56M | Sell |
5,277
-558
| -10% | -$260K | 0.86% | 32 |
|
|
2025
Q2 | $2.37M | Buy |
5,835
+39
| +0.7% | +$16.3K | 0.82% | 33 |
|
|
2025
Q1 | $2.89M | Sell |
5,796
-59
| -1% | -$32K | 1.11% | 22 |
|
|
2024
Q4 | $3.05M | Sell |
5,855
-32
| -0.5% | -$17.6K | 1.05% | 25 |
|
|
2024
Q3 | $3.64M | Buy |
5,887
+54
| +0.9% | +$32K | 1.3% | 18 |
|
|
2024
Q2 | $3.23M | Sell |
5,833
-657
| -10% | -$376K | 1.12% | 17 |
|
|
2024
Q1 | $3.77M | Buy |
6,490
+68
| +1% | +$38.2K | 1.4% | 16 |
|
|
2023
Q4 | $3.41M | Sell |
6,422
-24
| -0.4% | -$11.6K | 1.57% | 13 |
|
|
2023
Q3 | $3.27M | Buy |
6,446
+99
| +2% | +$52.8K | 1.5% | 12 |
|
|
2023
Q2 | $3.31M | Sell |
6,347
-140
| -2% | -$75.5K | 1.47% | 12 |
|
|
2023
Q1 | $3.74M | Sell |
6,487
-55
| -0.8% | -$31K | 1.79% | 8 |
|
|
2022
Q4 | $3.6M | Sell |
6,542
-243
| -4% | -$129K | 1.86% | 9 |
|
|
2022
Q3 | $3.44M | Sell |
6,785
-53
| -0.8% | -$29.7K | 1.78% | 9 |
|
|
2022
Q2 | $3.72M | Sell |
6,838
-25
| -0.4% | -$13.8K | 1.83% | 8 |
|
|
2022
Q1 | $4.06M | Buy |
6,863
+385
| +6% | +$221K | 1.64% | 10 |
|
|
2021
Q4 | $4.32M | Buy |
6,478
+172
| +3% | +$107K | 1.61% | 11 |
|
|
2021
Q3 | $3.6M | Buy |
6,306
+44
| +0.7% | +$24.1K | 1.52% | 8 |
|
|
2021
Q2 | $3.46M | Sell |
6,262
-492
| -7% | -$232K | 1.42% | 11 |
|
|
2021
Q1 | $3.08M | Buy |
6,754
+45
| +0.7% | +$21.5K | 1.49% | 9 |
|
|
2020
Q4 | $3.13M | Sell |
6,709
-45
| -0.7% | -$21.1K | 1.6% | 5 |
|
|
2020
Q3 | $3.06M | Buy |
6,754
+37
| +0.6% | +$15.3K | 1.62% | 5 |
|
|
2020
Q2 | $2.44M | Sell |
6,717
-62
| -0.9% | -$20.8K | 1.51% | 10 |
|
|
2020
Q1 | $2.27M | Sell |
6,779
-35
| -0.5% | -$11K | 1.53% | 11 |
|
|
2019
Q4 | $2.21M | Sell |
6,814
-165
| -2% | -$50K | 1.44% | 13 |
|
|
2019
Q3 | $2.03M | Sell |
6,979
-43
| -0.6% | -$12.3K | 1.45% | 12 |
|
|
2019
Q2 | $2.06M | Buy |
7,022
+599
| +9% | +$165K | 1.5% | 10 |
|
|
2019
Q1 | $1.76M | Buy |
6,423
+104
| +2% | +$25.9K | 1.37% | 15 |
|
|
2018
Q4 | $1.42M | Buy |
6,319
+10
| +0.2% | +$2.35K | 1.23% | 24 |
|
|
2018
Q3 | $1.39K | Buy |
6,309
+70
| +1% | +$16.1K | 0.98% | 26 |
|
|
2018
Q2 | $1.43K | Buy |
6,239
+190
| +3% | +$40.3K | 0.92% | 27 |
|
|
2018
Q1 | $1.25M | Buy |
6,049
+234
| +4% | +$49.1K | 0.88% | 31 |
|
|
2017
Q4 | $1.1M | Buy |
+5,815
| New | +$1.11M | 0.88% | 33 |
|
Other funds holding TMO
VCM
Front Row Advisors's TMO Position: Q1 2026 in Review
Front Row Advisors increased its Thermo Fisher Scientific (TMO) stake by 0.09% in Q1 2026, buying an estimated $2.71K and bringing the position to 5,290 shares worth $2.6M. The position accounts for 0.88% of the portfolio, ranked #32.
Front Row Advisors first reported a position in TMO in Q4 2017 and has held it in 34 quarters since. The position peaked at $4.32M in Q4 2021. 2,587 funds tracked by Wall St. Rank hold TMO as of Q1 2026.
- Front Row Advisors held 5,290 shares of Thermo Fisher Scientific worth $2.6M as of Q1 2026.
- Front Row Advisors bought 5 Thermo Fisher Scientific shares in Q1 2026, an estimated $2.71K.
- Thermo Fisher Scientific made up 0.88% of Front Row Advisors's portfolio in Q1 2026, its #32 holding.
- Front Row Advisors first reported a position in Thermo Fisher Scientific in Q4 2017 and has held it in 34 quarters since.
- Front Row Advisors's Thermo Fisher Scientific position peaked at $4.32M in Q4 2021.
- 2,587 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q1 2026.
Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.